Make your money go further for just 25p per day

Bioventix (AIM:BVXP) record results from this unusual high margin offering

05/10/2015 · Bioventix PLC (BVXP) 

The developer of high-affinity monoclonal antibodies for applications in clinical diagnostics, announced fantastic audited results for the year ended 30 June 2015. Pre-tax margins of over 70% and superb cash generation highlight the unusual (yet highly attractive) nature of this small business

We published a detailed commentary on this back in April 2015 which is worth a read.

For the year to 30th June 2015 revenue was up 23% to £4.3m and pre-tax profit up 39% to £3.1m (2013/14: £2.2m). The operating cash inflow was also a majestic £2.915m with free cash flow £2m after a modest £113k of capex. Year-end cash was £4.13m after the payment of equity…

Sign up and read the full article

Register to continue reading our content.

Get FREE access now

Already a member? Login


Previous article Next article

Have your say

Log in or register to view or add comments.

For access to the top news and insights from the investment world

REGISTER FREE

Become a Champion Investor for just £90 a year.
 
 

START FREE TRIAL

More on Bioventix PLC

Coronavirus impact: 30 March - a hint of resilience

30/03/2020 · Company Insights

The week has started with yet more dividend postponements and cancellations but also some fabulous results…


Champion Chatter – what costs more than £500,000 per gram?

08/10/2018 · Company Insights
News today includes fantastic results from a highly unusual small cap and a cracking load of…

More Company Insights

Is Rishi going to keep hospitality alive?

10/07/2020 · JD Wetherspoon · Young & Co.

Coronavirus impact: 10 July - a home recording lockdown winner

If Huawei is unravelled can BT and Vodafone pay their dividends?

10/07/2020 · BT · Vodafone